Alira Health

Alira Health

Rare Disease

Your Partner for Development and Commercialization of Rare Disease Treatments

Rare diseases present unparalleled challenges for patients. At Alira Health, we help companies develop and commercialize rare disease treatments with the intense focus on the unique needs of rare disease patients that is crucial to your success. With a continuum of patient-centric solutions, we work with you to successfully develop and provide life-changing treatments to the patients.

From clinical trial patient recruitment and retention to crafting a patient-centric product strategy, our transversal team stands by you every step of the way. 

rare disease pediatric patients

Full Lifecycle of Rare Disease Services for Your Success

Tailored and Truly Patient-Centric Approach for Rare Disease Treatments

Navigating the complexities of rare disease product development requires a nuanced approach. We know how to meet healthcare system expectations and offer an unmatched continuum of patient-centric solutions to aid you in this journey.

Our multidisciplinary team boasts: 

Patient Advisory Board

Patient engagement is key to bringing new drugs and medical devices to markets and securing patient access to these therapies across all disease areas. It is particularly important in rare diseases where patients are often the most expert on their disease.

When patients can be involved in the clinical development plan and creation of the trial protocol and are encouraged to provide in-trial feedback, they are more likely to stay in the trial, understand their responsibilities, and adhere to the protocol requirements.

Latest Rare Disease Insights

FAQs: Strategic Patient Engagement as a Game Changer for Your Product Success
Our patient engagement experts address some of the most popular questions about how to make patient engagement the core of a product development and commercialization strategy.
Creating Patient-Centric Clinical Trials in Rare Disease
For sponsors and CROs, patient engagement is critical. This guide explores specific opportunities for sponsors, CROs, and trial sites to develop patient-centric clinical trials for rare diseases.
Impact of the Orphan Drug Act on Rare Disease Patients and the Pharmaceutical Industry
Our experts reflect on the law and its impacts, both on life sciences companies and how they approach product development, and on patients with rare diseases and how to engage with them to successfully bring treatments to market.

Contact Us to Learn More About How We Can Support Your Needs


Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.